【藥品性質提示】 根據 2019 AGS Beers Criteria，本藥品為【潛在不適當用藥 (PIM)】，不建議用於老年人 (除非用於思覺失調、雙極症、或化療止吐)。

思覺失調症、重鬱症
Bipolar disorder, major depressive disorder (unipolar or adjunctive therapy with antidepressant), schizophrenia

Second Generation (Atypical) Antipsychotic

Absorption:Well absorbed
Distribution:
1. Vd: 4.9 L/kg
2. Protein binding: >99%, primarily to albumin
Metabolism: Hepatic dehydrogenation, hydroxylation and N-dealkylation via CYP2D6, CYP3A4
Pharmacodynamics:
1. Onset of action: Initial 1 to 3 weeks
2. Bioavailability: 87%

Hypersensitivity (eg, anaphylaxis, pruritus, urticaria) to aripiprazole or any component of the formulation.

C
Aripiprazole crosses the placenta

Aripiprazole and dehydro-aripiprazole are present in breast milk

Increased serum glucose, weight gain, Constipation, nausea, vomiting, Application site rash, Agitation, akathisia, anxiety, drowsiness, extrapyramidal reaction, fatigue, headache, sedated state, insomnia, Tremor

Bipolar disorder:
1. Acute manic or mixed episodes: Initial 10 to 15 mg once daily; may increase dose based on response and tolerability in 5 to 10 mg/day increments at intervals of 1 week up to a maximum of 30 mg/day. Maintenance treatment, continue dose and combination regimen that was used to achieve control of the acute episode.
2. Major depressive disorder (unipolar), treatment resistant (adjunctive therapy with antidepressant): Initial 2 to 5 mg/day; may increase dose based on response and tolerability in 5 mg increments at intervals 1 week up to a manufacturer's maximum of 15 mg/day. A further increase up to 20 mg/day may be necessary in some patients for optimal response.
Schizophrenia:
Initial 10 or 15 mg once daily; may increase dose based on response and tolerability in 5 mg increments at intervals 1 week up to a maximum of 30 mg/day.

Attention-deficit/hyperactivity disorder(ADHD): Limited data available:
1. >8 years: Initial 2.5 mg/day; may increase on a weekly basis by 2.5 mg/day increments as tolerated; maximum daily dose: 10 mg/day
2. 6 to 17 years: Initial 2 mg daily for 7 days, followed by 5 mg daily; subsequent dose increases may be made in 5 mg increments every 7 days, up to a maximum daily dose of 15 mg/day
Bipolar I disorder (acute manic or mixed episodes): (10 to 17 years)
Initial 2 mg daily for 2 days, followed by 5 mg daily for 2 days with a further increase to target dose of 10 mg daily; subsequent dose increases may be made in 5 mg increments, up to a maximum daily dose of 30 mg/day
Note: The safety of doses >30 mg/day has not been evaluated.
Conduct disorder (CD): (>6 years)
1. Initial (1) Patient weight <25 kg: 1 mg/day (2) 25 to 50 kg: 2 mg/day (3)51 to 70 kg: 5 mg/day (4) 70 kg: 10 mg/day
2. May titrate after 2 weeks to clinical effectiveness, maximum daily dose: 15 mg/day
Pervasive Developmental Disorder Not Otherwise Specified (PDD-NOS) or Asperger Disorder:
1. >4 years: Initial 1.25 mg/day with titration every 5 days in 1.25 mg/day increments as tolerated or clinically indicated
2. Prepubertal children: Initial 1.25 to 2.5 mg/day with titration every 3 to 5 days in 1.25 to 2.5 mg/day increments as tolerated or clinically indicated; maximum daily dose: 15 mg/day
3. Adolescents: Initial 2.5 to 5 mg/day with titration every 5 days in 2.5 to 5 mg/day increments as tolerated or clinically indicated; doses >5 mg/day were divided twice daily; if sleep disorder was reported, the dose was given in morning and/or at lunchtime; maximum daily dose: 15 mg/day
Schizophrenia: (For adolescents 13 to 17 years)
Initial: 2 mg daily for 2 days, followed by 5 mg daily for 2 days with a further increase to target dose of 10 mg daily; subsequent dose increases may be made in 5 mg increments up to a maximum daily dose of 30 mg/day
Note: 30 mg/day was not found to be more effective than the 10 mg/day dose.
Tourette syndrome, tic disorders: (> 6 years and Adolescents)
1. Patient weight <50 kg: Initial 2 mg daily for 2 days, then increase to target dose of 5 mg/day; in patients not achieving optimal control, dose may be further titrated at weekly intervals up to 10 mg/day.
2. Patient weight 50 kg: Initial 2 mg daily for 2 days, then increase to 5 mg/day for 5 days, then increase to target dose of 10 mg/day on day 8 of therapy; in patients not achieving optimal control, dose may be further titrated at weekly intervals in 5 mg/day increments up to 20 mg/day.

儲存於 30℃以下及小孩接觸不到之處所